Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis
ABSTRACT Background and Aims Concomitant administration of trastuzumab (Tra) and radiotherapy (RT) has been known as an effective strategy for treating HER2‐positive breast cancer (HER2+ BC) patients. Studies have investigated the incidence of cardiotoxicity due to this concomitant treatment, but th...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.70966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473239268458496 |
|---|---|
| author | Ali Jabbari Elham Mousavi Majid Nikoubin‐Boroujeni Shabnam Tabasi Nazila Arjmandi Noura Ghelishli Zahra Arab‐Bafrani |
| author_facet | Ali Jabbari Elham Mousavi Majid Nikoubin‐Boroujeni Shabnam Tabasi Nazila Arjmandi Noura Ghelishli Zahra Arab‐Bafrani |
| author_sort | Ali Jabbari |
| collection | DOAJ |
| description | ABSTRACT Background and Aims Concomitant administration of trastuzumab (Tra) and radiotherapy (RT) has been known as an effective strategy for treating HER2‐positive breast cancer (HER2+ BC) patients. Studies have investigated the incidence of cardiotoxicity due to this concomitant treatment, but the results are conflicting. This systematic review and meta‐analysis study evaluated the cardiac toxicity occurrence in patients undergoing Tra + RT. Methods A systematic review was conducted on the databases of PubMed, WOS, and Scopus up to 2024. The decline in left ventricular ejection fraction (LVEF) from baseline was assessed as a cardiac toxicity indicator, LVEF reduction Grade 1 (LVEF 60%–50%), Grade 2 (LVEF 50%–40%), and Grade 3 (LVEF 40%–20%). Results Seven studies meeting defined criteria were included in this investigation. This study examined the prevalence of LVEF‐grade 1–3 in HER2+ BC patients undergoing concurrent treatment with Tra and RT. The combined results showed a prevalence of decreased LVEF in Grades 1–3 as 21.4%, 4%, and 1%, respectively, with statistical significance (p < 0.05). Thus, among patients experiencing decreased LVEF, 70% were Grade 1, 25% were Grade 2, and 5% were Grade 3. Conclusion Cardiotoxic effects of chemotherapy and RT may accumulate and lead to heart failure so early diagnosis methods are advised. Concurrent RT with Tra is well‐tolerated clinically, and coadministration does not significantly raise primary cardiotoxicity. Cardiac toxicity may occur in some patients, requiring long‐term follow‐up to assess the impact of combining Tra and RT on heart function and its correlation with patient prognosis. |
| format | Article |
| id | doaj-art-fb542d3a33c844a8bfbb9973101ddc77 |
| institution | Kabale University |
| issn | 2398-8835 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj-art-fb542d3a33c844a8bfbb9973101ddc772025-08-20T03:24:12ZengWileyHealth Science Reports2398-88352025-06-0186n/an/a10.1002/hsr2.70966Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐AnalysisAli Jabbari0Elham Mousavi1Majid Nikoubin‐Boroujeni2Shabnam Tabasi3Nazila Arjmandi4Noura Ghelishli5Zahra Arab‐Bafrani6Ischemic Disorders Research Center Golestan University of Medical Sciences Gorgan IranMedical Mycology and Bacteriology Research Center Kerman University of Medical Sciences Kerman IranDepartment of Computer Engineering, Gorgan Branch Islamic Azad University Gorgan IranDepartment of Internal Medicine Golestan University of Medical Sciences Gorgan IranMetabolic Disorders Research Center Golestan University of Medical Sciences Gorgan IranDepartment of Pharmacy Mazandaran University of Medical Sciences Sari IranMetabolic Disorders Research Center Golestan University of Medical Sciences Gorgan IranABSTRACT Background and Aims Concomitant administration of trastuzumab (Tra) and radiotherapy (RT) has been known as an effective strategy for treating HER2‐positive breast cancer (HER2+ BC) patients. Studies have investigated the incidence of cardiotoxicity due to this concomitant treatment, but the results are conflicting. This systematic review and meta‐analysis study evaluated the cardiac toxicity occurrence in patients undergoing Tra + RT. Methods A systematic review was conducted on the databases of PubMed, WOS, and Scopus up to 2024. The decline in left ventricular ejection fraction (LVEF) from baseline was assessed as a cardiac toxicity indicator, LVEF reduction Grade 1 (LVEF 60%–50%), Grade 2 (LVEF 50%–40%), and Grade 3 (LVEF 40%–20%). Results Seven studies meeting defined criteria were included in this investigation. This study examined the prevalence of LVEF‐grade 1–3 in HER2+ BC patients undergoing concurrent treatment with Tra and RT. The combined results showed a prevalence of decreased LVEF in Grades 1–3 as 21.4%, 4%, and 1%, respectively, with statistical significance (p < 0.05). Thus, among patients experiencing decreased LVEF, 70% were Grade 1, 25% were Grade 2, and 5% were Grade 3. Conclusion Cardiotoxic effects of chemotherapy and RT may accumulate and lead to heart failure so early diagnosis methods are advised. Concurrent RT with Tra is well‐tolerated clinically, and coadministration does not significantly raise primary cardiotoxicity. Cardiac toxicity may occur in some patients, requiring long‐term follow‐up to assess the impact of combining Tra and RT on heart function and its correlation with patient prognosis.https://doi.org/10.1002/hsr2.70966cardiac toxicitychemotherapyconcurrent therapyradiotherapytrastuzumab |
| spellingShingle | Ali Jabbari Elham Mousavi Majid Nikoubin‐Boroujeni Shabnam Tabasi Nazila Arjmandi Noura Ghelishli Zahra Arab‐Bafrani Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis Health Science Reports cardiac toxicity chemotherapy concurrent therapy radiotherapy trastuzumab |
| title | Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis |
| title_full | Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis |
| title_fullStr | Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis |
| title_full_unstemmed | Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis |
| title_short | Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis |
| title_sort | cardiac toxicity under concurrent administration of trastuzumab anti her2 therapy and radiotherapy systematic review and meta analysis |
| topic | cardiac toxicity chemotherapy concurrent therapy radiotherapy trastuzumab |
| url | https://doi.org/10.1002/hsr2.70966 |
| work_keys_str_mv | AT alijabbari cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis AT elhammousavi cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis AT majidnikoubinboroujeni cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis AT shabnamtabasi cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis AT nazilaarjmandi cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis AT nouraghelishli cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis AT zahraarabbafrani cardiactoxicityunderconcurrentadministrationoftrastuzumabantiher2therapyandradiotherapysystematicreviewandmetaanalysis |